Miravant to seek FDA approval for SnET2

Santa Barbara, CA-Miravant Medical Technologies will file its first new drug application for marketing approval of PhotoPoint SnET2, for the treatment of wet age-related macular degeneration (AMD).

Related Content:

Pharmacy

Comparable conscious sedation methods address individual patient needs

Investigators uncover health care disparities among US patients

Investigators zoom in on future of dry eye treatment